ARCA BIOPHARMA, INC.

Company

Oruka Therapeutics, Inc.

Filed

April 5, 2024

Accession Number

0000902664-24-002769

A Schedule 13D is filed when an investor acquires more than 5% of a company's shares with an intent to influence control. Learn more about SC 13D filings →